Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBSep 7, 2013 · August 26th 2024. BGB-16673 has been granted FDA fast track designation based on findings from a phase 1/2 study of the oral agent in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of …
Survival Benefit for Chemotherapy Addition Demonstrated for ...
WEBDec 8, 2021 · Updated results of the SWOG S1007 RxPONDER trial (NCT01272037) showed significant differences in outcomes in premenopausal vs postmenopausal patients with hormone receptor (HR)–positive, HER2-negative breast cancer who had 1 to 3 positive lymph nodes and received adjuvant chemotherapy as well as endocrine therapy, according to an oral presentation by , given at the 2021 San Antonio Breast ...
FDA Grants Fast Track Designation to Enzastaurin in Newly …
WEBJul 17, 2020 · Enzastaurin (DB102), a first-in-class small molecule, has been granted a Fast Track designation by the FDA for the potential treatment of patients with newly diagnosed glioblastoma multiforme, Denova Biopharma announced in a press release. 1 "This Fast Track designation in glioblastoma is an important milestone in the development of DB102," said Xiao-Xiong Lu, PhD, chief technical officer ...
The Rationale for Adjuvant Ovarian Suppression in Patients With ...
WEBApr 17, 2019 · 1 Premenopausal women are at an increased risk of developing ABC and have a worse prognosis than older women. 2 In addition to having factors that put them at high risk for aggressive breast cancer subtypes, young premenopausal women (typically aged ≤40 years) are at an increased risk for long-term toxicities (ie, ovarian failure) associated with currently available treatments. 2,3 ...
Entinostat Receives Breakthrough Therapy Designation for …
WEBSep 12, 2013 · Entinostat, a novel HDAC inhibitor, in combination with exemestane has been granted a Breakthrough Therapy designation from the FDA for its potential to reverse resistance to hormonal therapies used to treat patients with advanced estrogen receptor (ER)-positive breast cancer. The new designation was based on results from the phase II …
Phase 1 Success of Targeting MUC16 in Patients With Recurrent …
WEBSep 14, 2022 · Ubamatamab, a novel MUC16 antibody, demonstrated evidence of durable responses in patients with recurrent ovarian cancer and showed an acceptable safety profile, according to a study presentation by David O'Malley, MD at the 2022 European Society of Oncology (ESMO) Annual Congress. 1 The phase 1 first-in-human study of ubamatamab (REGN4018; NCT03564340) included a total of 78 patients in the ...
Continuing Osimertinib Treatment After Progression Prolongs …
WEBJan 25, 2019 · The investigators said that continuing osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients. They suggested that further study will be needed, especially given the increasing role for osimertinib in the treatment of EGFR -mutant advanced NSCLC. Reference:
Abemaciclib Demonstrates Promising Clinical Activity in ...
WEBNov 20, 2018 · Abemaciclib is a selective oral ATP-competitive inhibitor of cyclin dependent kinases (CDKs) 4 and 6. “Abemaciclib targets CDK4 amplification, which occurs in more than 90% of well-differentiated and dedifferentiated liposarcomas,” explained Mark A. Dickson, MD, of Memorial Sloan Kettering Cancer Center in New York.
Enhancing Cancer Care With Integrative Oncology - Targeted Onc
WEBAug 7, 2024 · Integrative oncology is a growing field with the goal of improving cancer treatment through the incorporation of holistic approaches alongside conventional medical care. These therapies have also proved to be effective in reducing adverse effects like anxiety and depression in patients with cancer. 1,2. This approach includes therapies rooted ...
CheckMate-77T Trial Meets Primary EFS End Point in Resectable …
WEBOct 21, 2023 · Tina Cascone, MD, PhD, assistant professor, in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the main findings from the phase 3 CheckMate-77T trial (NCT04025879), which is evaluating the perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery ...